Iovance Biotherapeutics Inc
(HAM:2LB)
€
3.775
+0.090 (+2.44%)
Market Cap: 1.64 Bil
Enterprise Value: 1.41 Bil
PE Ratio: 0
PB Ratio: 2.54
GF Score: 44/100 Iovance Biotherapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript
Nov 17, 2021 / 04:20PM GMT
Benjamin Jay Burnett
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate
Welcome, everyone, to our next panel. My name is Ben Burnett, biotech analyst at Stifel, and I'm pleased to be joined by Madan Jagasia, SVP of Medical Affairs; and Jean-Marc Bellemin, CFO of Iovance Biotherapeutics. So thank you both for being here.
Jean;Marc Bellemin
Iovance Biotherapeutics, Inc. - CFO & Principal Accounting Officer
Thank you, Ben, for having us.
Benjamin Jay Burnett;Jean;Marc Bellemin
Stifel, Nicolaus & Company, Incorporated, Research Division - Associate
We will do a fireside chat. But obviously, for folks who are dialing in, please feel free to submit questions to the dashboard. I will be monitoring that or e-mail me at [email protected]. So let's just kick it off. Can you maybe just give us a quick update on Iovance where things are, just flag sort of what you think are near-term catalysts that we should be watching out for?
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot